Ceesay Abraham, Chief Executive Officer of an undisclosed company, has demonstrated a consistent pattern of selling shares in RAPP (Rapport Therapeutics Inc.) over the past several months, with no recorded purchases. According to SEC Form 4 filings, Abraham executed 24 sales between September 2025 and February 2026, totaling approximately $3.56 million in proceeds. The transactions were clustered around specific dates, with notable activity on September 17, 2025, where two large sales—$917,541.78 and $1,037,101.07—accounted for over half of the total sell value. Smaller but frequent disposals followed in subsequent months, including multiple sales on December 17, 2025, ranging from $15,985.39 to $83,861.91, and another concentrated batch on February 18, 2026, with individual transactions between $62,572.65 and $103,191.28.
The absence of any buy transactions suggests a clear divestment strategy, with Abraham systematically reducing his position in RAPP. The sales were executed at regular intervals, indicating either a prearranged trading plan or a deliberate effort to liquidate holdings over time. While the filings do not disclose the reasons behind the disposals, the sheer volume and consistency of the sales underscore a one-directional trend. The largest transactions occurred earlier in the period, with the later sales being comparatively smaller but still significant, reinforcing the sustained sell-side bias in Abraham’s trading activity.
AI-assisted summary